Higgs et al14 found that in patients with metastasized NSCLC and urothelial cancer who have been received PD‐L1 inhibitor (durvalumab), an increased IFNγ gene signature (IFNγ, CD274, LAG3, and CXCL9) is correlated with higher overall response rates and longer median progression‐free survival, which is independent of PD‐L1 expression assessed by immunohistochemistry, suggesting that IFNγ gene signature may stratify patients with improved outcomes to anti‐PD‐L1 antibodies. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.